All Stories

  1. Letter to the Editor Re: Commentary from the Melbourne Lung Transplant Group on the 2025 ISHLT Adult Lung Transplant DCD Report
  2. Booster Vaccination Against Invasive Pneumococcal Disease and Hepatitis B in Previously Vaccinated Solid Organ Transplant Recipients Without Seroprotection
  3. Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement
  4. Cytomegalovirus and Crohn’s disease as competing causes of small bowel inflammation after double-lung transplantation
  5. First report of bilateral Bronchial Rheoplasty for treating chronic bronchitis performed in a single procedure
  6. A European multi-center, randomized controlled trial of Pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation
  7. Impact of COVID-19 after lung transplantation: A retrospective multicenter comparison of clinical outcomes in Denmark and Sweden
  8. Delay in lung volume reduction surgery due to the COVID-19 pandemic: impact on patient performance and mortality
  9. Lung volume reduction for the treatment of emphysema
  10. The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients
  11. International experience of donation after circulatory death for lung transplantation. A special report from the International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation
  12. Early renal failure after primary thoracic organ transplantation
  13. Pulmonary adaptations to 12 wk of supervised high intensity interval training in COPD: a nonrandomized controlled pilot study
  14. Risk Factors for Pneumothorax After Treatment With Endobronchial Valves: A Cohort Study
  15. Allogeneic mesenchymal stromal cell therapy on primary graft dysfunction after lung transplantation
  16. Impact of donor age ≥65 years on graft survival in large lung transplant cohorts
  17. On the measurement of glomerular filtration rate: An odyssey into the milieu intérieur
  18. Survival in Patients With Evidence of Pulmonary Thromboembolism on Ventilation‐Perfusion SPECT 12 Weeks After Double Lung Transplantation: A Retrospective Cohort Study
  19. Vintage vitality: Embracing older donor lungs for transplants
  20. Leukocyte Count in Solid Organ Transplant Recipients After SARS-CoV-2 mRNA Vaccination and Infection
  21. Adenovirus Infections and Disease in Solid Organ Transplant Recipients: Incidence and Outcomes
  22. Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres
  23. E-cigarette or vaping product use-associated lung injury (EVALI). A case report of a 19-year-old male in Denmark
  24. Lung transplantation in a patient with severe bronchiolitis obliterans secondary to Castleman disease
  25. Transmission of human herpesvirus-8 through liver transplantation and development of post-transplantation Kaposi sarcoma: A case report
  26. Feasibility and accuracy of DireCt Lung Ultrasound Evaluation technique to monitor extravascular lung water in porcine lungs
  27. Management of Post-transplant Infections in Collaborating Hospitals (MATCH) Programme: a prospective cohort of all transplant recipients at Copenhagen University Hospital—Rigshospitalet, Denmark
  28. Post-Transplantation Seroprotection Rates in Liver, Lung, and Heart Transplant Recipients Vaccinated Pre-Transplantation against Hepatitis B Virus and Invasive Pneumococcal Disease
  29. A case of native lung hyperinflation after single lung transplantation treated with lung volume reduction coils
  30. The Use of Bronchial Rheoplasty in Emphysema Patients Previously Treated with Endoscopic Lung Volume Reduction: A Case Series
  31. Porcine lungs perfused with three different flows using the 8-h open-atrium cellular ex vivo lung perfusion technique
  32. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance
  33. Optimizing clinical outcomes for bronchoscopic lung volume reduction with Zephyr® valves
  34. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines
  35. Extracorporeal membrane oxygenation for acute lung injury in idiopathic inflammatory myopathies—a potential lifesaving intervention
  36. Assessing the role of phosphorylated S6 ribosomal protein in the pathological diagnosis of pulmonary antibody-mediated rejection
  37. Management of infectious disease syndromes in thoracic organ transplants and mechanical circulatory device recipients: a Delphi panel
  38. Long-term outcomes of lung transplantation with ex vivo lung perfusion technique
  39. Fraction of exhaled nitric oxide is higher in liver transplant recipients than in controls from the general population: a cohort study
  40. Predicting type 2 diabetes risk before and after solid organ transplantation using polygenic scores in a Danish cohort
  41. Predictors of reoperation after lung volume reduction surgery
  42. Differences in toll‐like receptor ligand‐induced cytokine concentrations before and after solid organ transplantation: A prospective, observational cohort study in a clinical setting
  43. Invasive Aspergillosis among Lung Transplant Recipients during Time Periods with Universal and Targeted Antifungal Prophylaxis—A Nationwide Cohort Study
  44. Graft survival in primary thoracic organ transplant recipients: A special report from the International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation
  45. Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience
  46. European Society of Organ Transplantation (ESOT) Consensus Statement on Prehabilitation for Solid Organ Transplantation Candidates
  47. Prediction of herpes virus infections after solid organ transplantation: a prospective study of immune function
  48. Severe Emphysema Treated with Bilateral Lung Sealant: A Case Series with Long-Term Follow-Up
  49. Performance of the 2009 CKDEPI, 2021 CKDEPI, and EKFC equations among high-risk patients in Denmark
  50. Associations between invasive aspergillosis and cytomegalovirus in lung transplant recipients: a nationwide cohort study
  51. ERS International Congress 2022: highlights from the Thoracic Surgery and Lung Transplantation Assembly
  52. Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus pneumoniae Infection. A Multiregional Epidemiological Study
  53. Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection
  54. Adverse Events Associated with Universal versus Targeted Antifungal Prophylaxis among Lung Transplant Recipients—A Nationwide Cohort Study 2010–2019
  55. Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation
  56. Effect of influenza vaccination in solid organ transplant recipients: A nationwide population-based cohort study
  57. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report—2022; focus on lung transplant recipients with chronic obstructive pulmonary disease
  58. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth pediatric lung transplantation report — 2022; focus on pulmonary vascular diseases
  59. The International thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-ninth adult heart transplantation report—2022; focus on transplant for restrictive heart disease
  60. The International thoracic organ transplant registry of the international society for heart and lung transplantation: Twenty-fifth pediatric heart transplantation report—2022; focus on infant heart transplantation
  61. Post-Transplantation Anemia and Risk of Death Following Lung Transplantation
  62. Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study
  63. Trends in underlying causes of death in solid organ transplant recipients between 2010 and 2020: Using the CLASS method for determining specific causes of death
  64. Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients
  65. Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions
  66. The utility of transbronchial lung biopsies to guide the treatment decision in patients with rheumatic inflammatory diseases: a retrospective cross-sectional study
  67. Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort
  68. Estimating Renal Function Following Lung Transplantation
  69. Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up
  70. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls
  71. National multi‐centre study found a low prevalence of severely impaired lung function in children and adolescents
  72. Achromobacter spp. in a Cohort of Non-Selected Pre- and Post-Lung Transplant Recipients
  73. Trends in underlying causes of death in solid organ transplant recipients between 2010 and 2020: Using the CLASS method for determining specific causes of death
  74. Intensive Care Antifungal Stewardship Programme Based on T2Candida PCR and Candida Mannan Antigen: A Prospective Study
  75. The evolution of the ISHLT transplant registry. Preparing for the future
  76. First patient with ILNEB syndrome due to pathogenic variants in ITGA3 surviving to adulthood
  77. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements
  78. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient characteristics
  79. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report — 2021; Focus on recipient characteristics
  80. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report — 2021; focus on recipient characteristics
  81. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report — 2021; Focus on recipient characteristics
  82. Lung ultrasound to phenotype chronic lung allograft dysfunction in lung transplant recipients. A prospective observational study
  83. Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing
  84. Protein Signatures of Remodeled Airways in Transplanted Lungs with Bronchiolitis Obliterans Syndrome Obtained Using Laser-Capture Microdissection
  85. An Observational Prospective Cohort Study of Incidence and Outcome of Streptococcus pneumoniae and Hemophilus influenzae Infections in Adult Solid Organ Transplant Recipients
  86. Bacterial Re-Colonization Occurs Early after Lung Transplantation in Cystic Fibrosis Patients
  87. Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational Study
  88. Lung transplantation for sarcoidosis: outcome and prognostic factors
  89. Incidence and Impact of Parvovirus B19 Infection in Seronegative Solid Organ Transplant Recipients
  90. Lung volume reduction surgery as salvage procedure after previous use of endobronchial valves
  91. Prognostic impact of ventilation‐perfusion defects and pulmonary diffusing capacity after single lung transplantation
  92. International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation
  93. Comparison of 81mKrypton and 99mTc-Technegas for ventilation single-photon emission computed tomography in severe chronic obstructive pulmonary disease
  94. Use of T Cell Mediated Immune Functional Assays for Adjustment of Immunosuppressive or Anti-infective Agents in Solid Organ Transplant Recipients: A Systematic Review
  95. Pseudomonas aeruginosa antibody response in cystic fibrosis decreases rapidly following lung transplantation
  96. Measles, Mumps, Rubella, and Varicella Zoster Virus Serology and Infections in Solid Organ Transplant Recipients During the First Year Posttransplantation
  97. Evidence of unilateral diaphragmatic paralysis on lung scintigraphy after double lung transplantation: impact on lung function and survival
  98. Felodipine and renal function in lung transplantation: A randomized placebo-controlled trial
  99. Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation
  100. Tuberculosis among Patients Undergoing Solid Organ Transplantation or Dialysis in a Low-Endemic Country, 2004-2017
  101. Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative
  102. Approaches to the Management of Sensitized Lung Transplant Candidates: Findings from an International Survey
  103. Evaluation of an electronic, patient‐focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation
  104. Survival in patients with scintigraphic evidence of pulmonary thromboembolism 12 weeks after double lung transplantation
  105. Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients
  106. Variation in Time to Peak Values for Different Lung Function Parameters After Double Lung Transplantation
  107. “Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”
  108. Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo:SOT study): a prospective non-interventional observational trial
  109. Torque-Teno virus viral load as a potential endogenous marker of immune function in solid organ transplantation
  110. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
  111. Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
  112. Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome
  113. Lobar Quantification by Ventilation/Perfusion SPECT/CT in Patients with Severe Emphysema Undergoing Lung Volume Reduction with Endobronchial Valves
  114. Chronic pain after bilateral thoracotomy in lung transplant patients
  115. Urgent lung allocation system in the Scandiatransplant countries
  116. Lung Ultrasound in the Assessment of Pulmonary Complications After Lung Transplantation
  117. Lung transplantation after ex vivo lung perfusion in two Scandinavian centres
  118. Laser-capture microdissection, mass spectrometry and immunohistochemistry reveal pathologic alterations in the extracellular matrix of transplanted lungs
  119. The “Coil Associated Opacity” in endoscopic emphysema treatment. Friend or foe?
  120. Classification of death causes after transplantation (CLASS)
  121. Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
  122. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients
  123. Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
  124. A Nordic Multicenter Study on Size Mismatch in Bilateral Lung Transplantation
  125. Bronchoalveolar Lavage Practices in Lung Transplantation: Results of a Large-scale International Survey
  126. Phosphorylated P70 S6 Kinase and S6 Ribosomal Protein Value as Diagnostic Marker of Antibody-mediated Rejection in Lung Allografts: A Multicenter Study
  127. Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia
  128. Donor Smoking and Older Age Increases Morbidity and Mortality After Lung Transplantation
  129. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation
  130. Current Practice of Airway Stenting in the Adult Population in Europe: A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP)
  131. Lung ultrasound for the diagnosis of post-operative complications after lung transplantation
  132. Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable?
  133. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study
  134. Is Histopathological Assessment Going to Remain the Gold Standard for Diagnosis of Pulmonary Allograft Rejection?
  135. Dichotomy in pulmonary graft- versus -host disease evident among allogeneic stem-cell transplant recipients undergoing lung transplantation: TABLE 1
  136. The impact of underlying disease on baseline pulmonary function values after lung transplantation
  137. Diffusion capacity as a predictor of prognosis after onset of CLAD
  138. Lung Transplantation after Ex-Vivo Lung Perfusion in Two Scandinavian Centres
  139. Low Correlation in Longevity between Lung Grafts from the Same Donor
  140. FVC, TLC and CT as Independent Predictors for Prognosis after Onset of CLAD
  141. Long-term survival in lung transplant recipients depending on icu length of stay: outcome in a series of 653 consecutive patients
  142. Colonization of bacteria after lung transplantation in cystic fibrosis (CF) patients occurs early but does not impact survival
  143. Impact of Age and Smoking History on the Selection of Donors for Lung Transplantation
  144. Prognosis of patients with alpha1-antitrypsine deficiency on long-term oxygen therapy
  145. Early laparotomy after lung transplantation: Increased incidence for patients with α1-anti-trypsin deficiency
  146. Endoscopic treatment of native lung hyperinflation using endobronchial valves in single-lung transplant patients: a multinational experience
  147. Catch-Up Growth Occurs after Diarrhea in Early Childhood
  148. Age-Related Decline in Lung Function in Patients Without CLAD After Double Lung Transplantation
  149. A Zero 90-Day Mortality After Lung Transplantation - What Is the Price?
  150. Restrictive Allograft Syndrome (RAS) in Lung Transplant Recipients Carries Uncertain Additional Prognostic Significance as Compared To BOS
  151. HIV testing of patients diagnosed with tuberculosis increased in Denmark during the period from 2007 to 2009
  152. Long Term Outcome after Bronchial Artery Revascularization in Double Lung Transplantation – A More Than Fifteen Year Follow-Up Study
  153. Lung Transplant Recipients Suspected of Antibody Mediated Rejection Treated with Plasmapheresis Have a Poor Prognosis
  154. Wasting Is Associated with Stunting in Early Childhood
  155. 726 Endoscopic Treatment of Native Lung Hyperinflation with One-Way Valves in Single Lung Transplant Patients: A Multinational Experience
  156. 526 Chronic Allograft Dysfunction after Lung Transplantation. A Comparison of RAS vs. BOS
  157. Treatment of Intractable Interstitial Lung Injury with Alemtuzumab after Lung Transplantation
  158. Community cohort study of Cryptosporidium parvum infections: sex-differential incidences associated with BCG and diptheria–tetanus–pertussis vaccinations
  159. Outbreak of Salmonella Braenderup infections associated with Roma tomatoes, northeastern United States, 2004: a useful method for subtyping exposures in field investigations
  160. Community cohort study of rotavirus and other enteropathogens: Are routine vaccinations associated with sex-differential incidence rates?
  161. Intussusception in Early Childhood: A Cohort Study of 1.7 Million Children
  162. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection
  163. Cohort Study of Guinean Children: Incidence, Pathogenicity, Conferred Protection, and Attributable Risk for Enteropathogens during the First 2 Years of Life
  164. EnterotoxigenicEscherichia coliInfections and Diarrhea in a Cohort of Young Children in Guinea‐Bissau
  165. Protective Immunity after Natural Rotavirus Infection: A Community Cohort Study of Newborn Children in Guinea‐Bissau, West Africa
  166. Seven years' experience withCryptosporidium parvumin Guinea-Bissau, West Africa
  167. Community-based controlled trial of dietary management of children with persistent diarrhea: sustained beneficial effect on ponderal and linear growth